Silver Book Fact

Drug resistant infections cost $16.6 – $26 billion to US healthcare system annually

Drug-resistant infections cost the U.S. healthcare system between $16.6 and $26 billion in extra costs each year.

Roberts, Rebecca R., Bala Hota, Ibrar Ahmad, R. Douglas Scott, Susan D. Foster, Fauzia Abbasi, Shari Schabowski, Linda M. Kampe, Ginerva G. Ciavarella, Mark Supino, Jeremy Naples, Ralph Cordell, Stuart B. Levy, and Robert A. Weinstein. Hospital and Societal Costs of Antimicrobial-Resistant Infections in a Chicago Teaching Hospital: Implicatons for antibiotic stewardship. Clin Infect Dis. 2009; 49(8): 1175-84. http://cid.oxfordjournals.org/content/49/8/1175.full

Reference

Title
Hospital and Societal Costs of Antimicrobial-Resistant Infections in a Chicago Teaching Hospital: Implicatons for antibiotic stewardship
Publication
Clin Infect Dis
Publication Date
2009
Authors
Roberts, Rebecca R., Bala Hota, Ibrar Ahmad, R. Douglas Scott, Susan D. Foster, Fauzia Abbasi, Shari Schabowski, Linda M. Kampe, Ginerva G. Ciavarella, Mark Supino, Jeremy Naples, Ralph Cordell, Stuart B. Levy, and Robert A. Weinstein
Volume & Issue
Volume 49, Issue 8
Pages
1175-84
URL
Read Full Resource

Categories

  • Cost of Disease
  • Economic Burden

Related Facts

  • Sepsis hospitalization rate increases with age
    The rate of hospitalization for sepsis/septicemia in 2008 was around 30 times higher for patients ages 85 and older, than for those under the age of 65.  
  • Primary sources of HAIs
    Around 2/3 of all HAIs are central-line associated bloodstream infections, catheter-associated urinary tract infections, and ventilator-associated pneumonia. Surgical site infections and Clostridium difficile (C. difficile) are also common HAIs.  
  • ~1.7 million Americans develop hospital-acquired HAIs annually
    Approximately 1.7 million Americans develop hospital-acquired HAIs each year.  
  • HAI Annual Cost
    Healthcare-associated infections in US hospitals cost $96–$147 billion annually.  
  • Drug-resistant MRSA expensive to treat
    As an example, the median treatment cost for drug-resistant MRSA patients over a 6-month period was 118% higher than the cost of treating drug-susceptible MRSA strains.